Skip to content

Local microvascular reactivity to Acetylcholine in patients with essential hypertension: possible interactions with the local renin-angiotensin system.

Local microvascular reactivity to Acetylcholine in patients with essential hypertension: possible interactions with the local renin-angiotensin system. - Local microvascular reactivity to Ach in hypertensive patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON31352
Enrollment
32
Registered
2007-04-26
Start date
2007-06-01
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

high blood pressure Hypertension

Interventions

Local application of Acetylcholine, Sodium Nitroprusside, Angiotensin II and placebo in the bulbar conjunctiva (eye drops) and the finger skin (iontophoresis).

Sponsors

Academisch Ziekenhuis Maastricht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria hypertensive patients: - Age:18-65 year - Caucasian - Untreated blood pressure > 140/90 mmHg - In consultation with the internist, anti-hypertensive medication will be stopped 3 weeks prior to the start of the experiment. ;Inclusion criteria normotensive volunteers: - Age:18-65 year - Caucasian - Blood pressure

Exclusion criteria

Exclusion criteria: - Secondary hypertension - Diabetes mellitus according to the criteria of the ADA - Kidney failure: serum creatinine > 150 µmol/l - Unable to stop blood pressure lowering medication during a period of 3 weeks - Use of blood cholesterol lowering medication - (Hypertensive) retinopathy, glaucoma or conjunctival disease - Connective tissue disease - Contact lenses

Design outcomes

Primary

MeasureTime frame
Changes in vascular diameters of bulbar conjunctiva, and changes in skin laser-Doppler flux.

Secondary

MeasureTime frame
/

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)